REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 395-401

  Sekikawa, A ^a   Fukui, H ^b   Zhang, X ^b   Maruo, T ^a   Tsumura, T ^a   Okabe, Y ^a   Wakasa, T ^a   Osaki, Y ^a   Chiba, T ^c   Tomita, T ^b   Oshima, T ^b   Watari, J ^b   Miwa, H ^b  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Biomarker; Chemotherapy; Gastric cancer; Prognosis; REG

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARDIA CARCINOMA; CELL SURVIVAL; DISEASE COURSE; FOLLOW UP; GENE EXPRESSION; GENE INDUCTION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGENERATING GENE IALPHA; STOMACH CANCER; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LITHOSTATHINE; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84873703870     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.572     Document Type: Article

References (29)

1. BoküN (2008) Chemotherapy for metastatic gastric cancer in Japan. Int J Oncol 13: 483-487.
2. ChaüI, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22: 2395-2403. (Pubitemid 41121931)
3. Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, Kim JH, Kim WH, Lee JS (2011) Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: Orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol 28: 991-998.
4. Dhar DK, Udagawa J, Ishihara S, Otani H, Kinoshita Y, Takasawa S, Okamoto H, Kubota H, Fujii T, Tachibana M, Nagasue N (2004) Expression of regenerating gene I in gastric cancer adenocarcinomas. Cancer 100: 1130-1136.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
6. Fukui H, Fujii S, Takeda J, Kayahara T, Sekikawa A, Nanakin A, Suzuki K, Hisatsune H, Seno H, Sawada M, Fujimori T, Chiba T (2004) Expression of Reg Ia protein in human gastric cancers. Digestion 69: 177-184. (Pubitemid 38813027)
7. Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan S, Okamoto H, Chiba T (1998) Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 115: 1483-1493. (Pubitemid 28545999)
8. Ichikawa W, Sasaki Y (2006) Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 17: 1665-1672. (Pubitemid 44687335)
9. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer 1: 10-24.
10. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150. (Pubitemid 46655601)
11. Kodera Y, Ito Y, Ohashi N, Nakayama G, Koike M, Fujiwara M, Nakao A (2011) Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy. Hepatogastroenterology 58: 1041-1045.
12. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9: 215-221.
13. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18: 886-891. (Pubitemid 47054086)
14. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338. (Pubitemid 37328853)
15. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98: 832-839. (Pubitemid 351272605)
16. OhtsüA (2008) Chemotherapy for metastatic gastric cancer: Past, present, and future. J Gastroenterol 43: 256-264. (Pubitemid 351650035)
17. Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, RyüKW, Lee JH, Rhee J, Park YI, Kim NK (2011) CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer 104: 1126-1134.
18. Satomura Y, SawabüN, Ohta H, Watanabe H, Yamakawa O, Motoo Y, Okai T, Toya D, Makino H, Okamoto H (1993) The immunohistochemical evaluation of PSP/reg-protein in normal and diseased human pancreatic tissues. Int J Pancreatol 13: 59-67. (Pubitemid 23086379)
19. Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, Chiba T, Fujimori T (2008) REG Ia protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis 29: 76-83. (Pubitemid 351201744)
20. Sekikawa A, Fukui H, Fujii S, Takeda J, Nanakin A, Hisatsune H, Seno H, Takasawa S, Okamoto H, Fujimori T, Chiba T (2005) REG Ia protein may function as a trophic and/or anti-apoptotic factor in the development of gastric cancer. Gastroenterology 128: 642-653. (Pubitemid 40585367)
21. Takaishi S, Wang TC (2007) Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci 98: 284-293. (Pubitemid 46195596)
22. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H (1988) A novel gene activated in regenerating islets. J Biol Chem 263: 2111-2114. (Pubitemid 18060259)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216. (Pubitemid 30099779)
24. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N (2003) Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci 94: 15-21. (Pubitemid 36575852)
25. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, Dussaulx E, Lacorte JM, Chambaz J, Lacasa M, Lesuffleur T (2003) REG IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 103: 185-193. (Pubitemid 35461510)
26. Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H (1990) Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. J Biol Chem 265: 7432-7439.
27. Yamagishi H, Fukui H, Sekikawa A, Kono T, Fujii S, Ichikawa K, Tomita S, Imura J, Hiraishi H, Chiba T, Fujimori T (2009) Expression profile of REG family proteins REG Ia and REG IV in advanced gastric cancer: Comparison with mucin phenotype and prognostic markers. Mod Pathol 22: 906-913.
28. Yonemura Y, Sakurai S, Yamamoto H, EndoüY, Kawamura T, BandoüE, Elnemr A, Sugiyama K, Sasaki T, Akiyama T, Takasawa S, Okamoto H (2003) REG gene expression is associated with the infiltrating growth of gastric cancer. Cancer 98: 1394-1400. (Pubitemid 37151493)
29. Zhang J, Roberts TM, Shivdasani RA (2011) Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141: 50-61.